At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
40mg lurasidone +1 moredrug
Likely dose
40mg lurasidonefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects
In Brief
A Phase 1 clinical trial evaluating 40mg lurasidone and placebo for Schizophrenia. Completed, enrolled 14 participants across 1 site.
Detailed Summary
To evaluate the pharmacokinetic (PK) characteristics after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects. To evaluate the safety and tolerance after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesChina
CollaboratorsXuhui Central Hospital, Shanghai
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
Primary CompletionApr 2014
First PostedJun 2014
TodayJul 2026
First PostedJun 25, 2014
Enrollment StartApr 1, 2014
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 12.0 years ago
Interventions
40mg lurasidonedrug
placebodrug